View video here
View video here
According to the report, more than 92 million adults in China have diabetes, and nearly 150 million more are well on their way to developing it. The disease is more common in people with large waistlines and in those who live in cities, the report indicates. “For every person in the world with HIV there [...]
According to the report, more than 92 million adults in China have diabetes, and nearly 150 million more are well on their way to developing it. The disease is more common in people with large waistlines and in those who live in cities, the report indicates. “For every person in the world with HIV there are three people in China with diabetes,” said David Whiting, an epidemiologist with the International Diabetes Federation, who was not involved in the research. The Federation projected last year that some 435 million people would have diabetes by 2030. “With this new study, we’re going to have to rerun our estimate,” Whiting told Reuters Health.
The report, published Thursday in the New England Journal of Medicine, is based on a nationally representative sample of more than 46,000 people who were tested for diabetes. For each person, doctors measured blood sugar levels up to two hours after subjects had swallowed a sugar solution or, in cases where diabetes was suspected, eaten a bun. Because people with diabetes can’t use the sugar in their blood effectively, a high blood sugar level indicates disease.
Read more, source: Reuters
As the excitement around President Obama’s healthcare plans continues, the fact that the bill still contains provisions ensuring 12-year market exclusivity for the makers of novel biotech drugs in the USA has slipped under the radar somewhat.
Kathleen Jaeger, president of the Generic Pharmaceutical Association, said the passage of healthcare reform “provides both good and [...]
As the excitement around President Obama’s healthcare plans continues, the fact that the bill still contains provisions ensuring 12-year market exclusivity for the makers of novel biotech drugs in the USA has slipped under the radar somewhat.
Kathleen Jaeger, president of the Generic Pharmaceutical Association, said the passage of healthcare reform “provides both good and bad news for consumers”, claiming that more Americans getting insurance coverage and more seniors having access to generic medicines is a positive. However, she says the bill “provides a biogeneric pathway in name only, giving false hope to patients who desperately need access to life-saving biogeneric medicines”.
Ms Jaeger goes on to say that “simply put, the bill fails to infuse competition and choice into the healthcare system due to the excessive and unprecedented market exclusivity protections for the brand industry”. She adds that “until the brand evergreen loophole is closed and the indefinite brand biologic monopolies are addressed, our healthcare system will not see true savings from biogenerics for decades”.
Read more, source: PharmaTimes
Bangladesh can export drugs worth Tk200 billion a year if the local medicine makers upgrade their facilities to a level that’ll enable them to do contract manufacturing for foreign pharmaceuticals, experts said Sunday. Drug manufacturing is becoming costly in the highly regulated western market, prompting major pharmaceutical companies to contract out drug making to companies [...]
Bangladesh can export drugs worth Tk200 billion a year if the local medicine makers upgrade their facilities to a level that’ll enable them to do contract manufacturing for foreign pharmaceuticals, experts said Sunday. Drug manufacturing is becoming costly in the highly regulated western market, prompting major pharmaceutical companies to contract out drug making to companies in low-cost countries.
“Contract manufacturing is one of the major growth areas in global drug industry. And Bangladeshi companies can be one of the major beneficiaries of the fast growing sector,” said ABM Faroque, president of Bangladesh Pharmaceuticals Society (BPS). “The country’s top 10-12 drug makers have state-of-the-art drug plants and if they upgrade their facilities further, they’ll be in a position to sign lucrative contract manufacturing deals with foreign companies,” said Faroque, also a professor of pharmaceutical technology at Dhaka University.
Read more, source: The Financial Express
The National Reimbursement Drug List is being updated for the first time since 2004 with many Western drugs added to the category that entitles patients to a rebate of up to 50 percent. New entrants include Astra’s cholesterol fighter Crestor and its heartburn pill Nexium, along with Sanofi’s anti-clotting medicine Plavix. The fact that hospitals [...]
The National Reimbursement Drug List is being updated for the first time since 2004 with many Western drugs added to the category that entitles patients to a rebate of up to 50 percent. New entrants include Astra’s cholesterol fighter Crestor and its heartburn pill Nexium, along with Sanofi’s anti-clotting medicine Plavix. The fact that hospitals dominate dispensing in China and are able to extract higher absolute mark-ups on Western drugs should also drive market share increases, Morgan Stanley said in a report on Monday. Pharmaceutical spending current accounts for less than 5 percent of China’s GDP but the brokerage expects this to grow by 18 percent annually, representing a “windfall” for Western manufacturers over the coming three to five years.
Read more, source: Reuters
Pharmaceutical companies in Turkey face considerable challenges in 2010. From being one of the most prosperous markets in Central and Eastern Europe (CEE), short-term market performance is due to be substantially impaired by pricing and reimbursement revisions. Nevertheless, longer-term dynamics remain positive for drugmakers. This is reflected in the Business Environment Ratings for Q210, where [...]
Pharmaceutical companies in Turkey face considerable challenges in 2010. From being one of the most prosperous markets in Central and Eastern Europe (CEE), short-term market performance is due to be substantially impaired by pricing and reimbursement revisions. Nevertheless, longer-term dynamics remain positive for drugmakers. This is reflected in the Business Environment Ratings for Q210, where Turkey is ranked the fourth most attractive market in the region, slipping one place this quarter.
Double-digit growth has been an undisrupted trend for drug expenditure over the past five years, with strong economic growth and increasing government contributions key market drivers. Pharmaceutical expenditure under Turkey’s Green Card grew 35% in 2009, according to data recently published by the Ministry of Finance. A 326% month-on-month (m-o-m) surge in spending in December 2009 overinflated full-year spending figures, which had looked on course for an increase of around 15% based on November MAT data.
Read more, source: PR Inside
Sign up for our mailing list:
Thanks for visiting!
- Access Asia Pacific Biotech Brazil China Counterfeit developing countries Drug Prices Emerging Markets Ethics Generics Health Insurance HIV/AIDS India Industrial Policy Innovation Intellectual Property Managed health care medicines Nanotechnology News pharmaceutical pharmaceutical policy Pharmacists Pharmacoeconomics Philippines Poverty public policy Quality R&D Regulatory Affairs Reimbursement Risk sharing Russia Singapore South Africa Supply Chain Taiwan Trade Vaccines
Archives
- October 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- November 2011
- September 2011
- April 2011
- February 2011
- January 2011
- December 2010
- November 2010
- September 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- October 2008
- July 2008
- October 2007
- November 2006
- October 2006
- November 2005
